Tirzepatide

Dual GIP / GLP-1 receptor agonist for superior weight loss and glycemic control.

Quick Reference

Dose: 2.5 → 15 mg
Frequency / schedule: Once weekly
Route: Subcutaneous
Timing: Same day each week (morning or evening)
Fasting: Not required — can be taken with or without food
Cycle: Ongoing
Time off: Weight regain common on stop
Common vial strengths: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg research vials

How this works

Tirzepatide simultaneously activates GLP-1 and GIP receptors. GLP-1 suppresses appetite, slows gastric emptying, and improves glucose-dependent insulin secretion. GIP further enhances insulin sensitivity and amplifies the metabolic effect. Dual action produces greater weight loss than selective GLP-1 agonists. Half-life ~5 days → once-weekly dosing.

Benefits + side effects

Potential Benefits

Up to ~21–22% average weight loss
Strong HbA1c reductions
Improvements in lipids and blood pressure

Side Effects

GI effects (nausea, diarrhea, vomiting, constipation) — reduced by slow titration
Mild injection-site reactions

Dosing / Protocol

Reference Protocol

Phase / week	Dose	Frequency	Timing	Notes
Weeks 1–4	2.5 mg	Once weekly	Same day	Tolerance / GI adaptation
Weeks 5–8	5 mg	Once weekly	Same day	First therapeutic
Weeks 9–12	7.5 mg	Once weekly	Same day	Continue titration
Weeks 13–16	10 mg	Once weekly	Same day	Higher dose
Further	12.5–15 mg	Once weekly	Same day	Higher research range

Timing + Fasting Notes

- Inject on the exact same day and roughly the same time each week. - Food has minimal impact. - Evening dosing is popular so potential nausea occurs overnight.

Reconstitution

Common vial strengths5 mg, 10 mg, 15 mg, 20 mg, 30 mg research vials

Approved preparation example
10 mg vial + 1 mL BAC = 10 mg/mL. Or 10 mg + 2 mL = 5 mg/mL for easier unit math.

Practical Reference

Storage: Lyophilized frozen or refrigerated; reconstituted refrigerated, use within 28 days
Route / injection context: Subcutaneous
Bloodwork / markers: Weight, HbA1c, fasting glucose, lipids
Common vial strengths: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg research vials
Cycle / time off: Ongoing · Weight regain common on stop
Practical notes: Research peptide — reconstitute yourself. Never skip titration steps. Rotate injection sites.

References

Tirzepatide Once Weekly for the Treatment of ObesityNew England Journal of Medicine · 2022 · DOI 10.1056/NEJMoa2206038

CLINICAL TRIAL

Dataset reference context: SURMOUNT and SURPASS trial data

THE SIGNAL · SENT TWICE A MONTH

Stay ahead of the research without living on PubMed.

Peptide references, research worth knowing, new FEMETRIC tools, and meaningful testing updates. Twice a month. No daily emails.By subscribing, you agree to receive The Signal from FEMETRIC. Unsubscribe anytime.

Search Femetric